To compare the anti-craving effect of three drugs Naltrexone, Topiramate and Baclofen in patients using alcohol.

Comparison of anti-craving effect of Naltrexone, Topiramate, Baclofen in patients of alcohol dependence

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/05/019346

Enrollment

Registered

2019-05-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F102- Alcohol dependence

Interventions

Intervention1: Naltrexone Topiramate Baclofen: Naltrexone 50 mg/day PO Topiramate 50 mg/day PO Baclofen 20 mg/day PO Control Intervention1: Naltrexone: Naltrexone 50mg/day and escalated 50mg/day on as

Eligibility

Inclusion criteria

Inclusion criteria: 2. Availability of reliable informant 3. Fulfilling ICD-10 diagnostic criteria for alcohol dependence 4. Patient suitable for out-patient treatment 5. Patient consenting to participate in study

Exclusion criteria

Exclusion criteria: 1. Presence of significant medical comorbidity requiring/undergoing treatment (as assessed by through physical examination and routine laboratory screening) 2. Presence of another co existing major psychiatric disorder 3. Presence of another drug abuse except nicotine 4. Hypersensitivity to any of these drugs

Design outcomes

Primary

Measure	Time frame
CravingTimepoint: 1 week, 2 week, 3 week, 4 week	—

Secondary

Measure	Time frame
cravingTimepoint: 1 month	—

Countries

India

Contacts

Public ContactPooja Yadav

SGT University

drvpmahla@gmail.com8800222330

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026